Northwest Biotherapeutics

Showcase Sponsor

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines.  The Company's DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and various potential  Phase II trials are anticipated, including in combination with checkpoint inhibitor drugs.  The Company's DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers,  and various potential Phase II trials are anticipated.


Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071